Patents by Inventor Ken UCHIBORI

Ken UCHIBORI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
    Patent number: 11419871
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: August 23, 2022
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Ryohei Katayama, Ken Uchibori, Naoya Fujita
  • THERAPEUTIC AGENT FOR LUNG CANCER THAT HAS ACQUIRED EGFR-TKI RESISTANCE
    Publication number: 20200397786
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Application
    Filed: September 8, 2020
    Publication date: December 24, 2020
    Inventors: Ryohei Katayama, Ken Uchibori, Naoya Fujita
  • Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
    Patent number: 10813933
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: October 27, 2020
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Ryohei Katayama, Ken Uchibori, Naoya Fujita
  • THERAPEUTIC AGENT FOR LUNG CANCER THAT HAS ACQUIRED EGFR-TKI RESISTANCE
    Publication number: 20190160066
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Application
    Filed: May 17, 2017
    Publication date: May 30, 2019
    Inventors: Ryohei KATAYAMA, Ken UCHIBORI, Naoya FUJITA